AI Article Synopsis
- Respiratory syncytial virus (RSV) significantly impacts healthy infants, leading to many hospitalizations worldwide, and understanding its burden in Europe is critical for future vaccine and treatment development.
- A study will follow 10,000 healthy infants over three years to track RSV-related hospitalizations through questionnaires and medical records, focusing on a smaller group of 1,000 for detailed respiratory sampling.
- The main goal is to gather data on the rate of RSV-related hospitalizations and respiratory infections in infants, which will enhance knowledge on RSV's impact and aid healthcare strategies.
Article Abstract
Background: Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants worldwide. Although prematurity and cardiopulmonary disease are risk factors for severe disease, the majority of infants hospitalized with RSV are previously healthy. Various vaccines and therapeutics are under development and expected to be available in the near future. To inform the use of these new vaccines and therapeutics, it is necessary to determine the burden of RSV disease in Europe. We will prospectively follow-up a birth cohort to obtain incidence data on RSV acute respiratory tract infection (ARTI).
Methods: Multicenter prospective study of a birth cohort consisting of 10 000 healthy infants, recruited during 3 consecutive years. RSV associated hospitalization in the first year of life will be determined by questionnaires and hospital chart reviews. A nested cohort of 1000 infants will be actively followed. In case of ARTI, a respiratory sample will be collected for RSV molecular diagnosis.
Results: The primary outcome is the incidence rate of RSV-associated hospitalization in the first year of life. In the active cohort the primary outcome is RSV associated ARTI and MA-ARTI.
Conclusions: We will provide key information to fill the gaps in knowledge about the burden of RSV disease in healthy infants.
Clinical Trials Registration: NCT03627572.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiaa310 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alveolar Macrophages in Viral Respiratory Infections: Sentinels and Saboteurs of Lung Defense.
Int J Mol Sci
January 2025
Department of Pathology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany.
Respiratory viral infections continue to cause pandemic and epidemic outbreaks in humans and animals. Under steady-state conditions, alveolar macrophages (AlvMϕ) fulfill a multitude of tasks in order to maintain tissue homeostasis. Due to their anatomic localization within the deep lung, AlvMϕ are prone to detect and react to inhaled viruses and thus play a role in the early pathogenesis of several respiratory viral infections.
View Article and Find Full Text PDFThe Molecular Basis of Asthma Exacerbations Triggered by Viral Infections: The Role of Specific miRNAs.
Int J Mol Sci
December 2024
Department and Clinic of Paediatrics, Allergology and Cardiology, Wroclaw Medical University, ul. Chałubińskiego 2a, 50-368 Wrocław, Poland.
Viral respiratory infections are a significant clinical problem among the pediatric population and are one of the leading causes of hospitalization. Most often, upper respiratory tract infections are self-limiting. Still, those that involve the lower respiratory tract are usually associated with asthma exacerbations, leading to worsening or even the initiation of the disease.
View Article and Find Full Text PDFSynthesis and Antiviral Evaluation of 5-(4-Aryl-1,3-butadiyn-1-yl)-uridines and Their Phosphoramidate Pronucleotides.
Molecules
December 2024
Institute of Organic and Analytical Chemistry (ICOA UMR 7311), CNRS, University of Orleans, F-45067 Orléans, France.
The emergence of RNA viruses driven by global population growth and international trade highlights the urgent need for effective antiviral agents that can inhibit viral replication. Nucleoside analogs, which mimic natural nucleotides, have shown promise in targeting RNA-dependent RNA polymerases (RdRps). Starting from protected 5-iodouridine, we report the synthesis of -substituted-(1,3-diyne)-uridines nucleosides and their phosphoramidate prodrugs.
View Article and Find Full Text PDF"We've wanted to vaccinate against it and now we can": views of respiratory syncytial virus disease and immunisation held by caregivers of Aboriginal children in Perth, Western Australia.
Aust N Z J Public Health
January 2025
Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, University of Western Australia, Perth, Western Australia, Australia; School of Population Health, Curtin University, Perth, Western Australia, Australia. Electronic address:
Objective: Respiratory syncytial virus (RSV) is a major cause of respiratory infection with a higher burden in Aboriginal and Torres Strait Islander infants and children. We conducted a pilot qualitative study identifying disease knowledge and willingness to immunise following the changing immunisation landscape for infant RSV in 2024.
Methods: Yarning groups were held with a convenience sample of parents/carers of Aboriginal children attending playgroup at a metropolitan Aboriginal Health Service in Western Australia.
Recommendation for the use of respiratory syncytial virus vaccines.
J Microbiol Immunol Infect
January 2025
Division of Infectious Diseases, Department of Pediatrics, Chang Gung Children's Hospital, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taiwan.
Respiratory syncytial virus (RSV) is the most common pathogen for young children hospitalized with bronchiolitis and pneumonia. Most infections occur below 1 year of age. RSV is also a significant viral pathogen for adults with respiratory tract infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!